TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02585856

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PDT
Description: Patients with unresectable CCA are performed PDT with ERCP after porfimer sodium （chongqing ray high medical instrument co., LTD，Chongqing, China) i.v. at a dose of 2 mg/kg at 48 h.~PDT procedure: for light distribution, flexible cylindrical diffuser probes mounted on 400-mm quartz fibres with an active distal tip length of 2 cm （chongqing ray high medical instrument co., LTD，Chongqing, China) is used. The light source was a diode laser system with a maximum power output of 2 Wand a wavelength of 633.3 nm. The power emitted by the diffuser tip was calibrated to 400 mW/cm before PDT was administered using an integrating sphere power meter. The mean irradiation time was 452 s (range: 400-600 s), using a power density of 300-400 mW/cm and an energy dose of 180-200 J/cm (of diffuser length).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stent
Description: Patients with unresectable CCA are performed with ERCP, one or several plastic biliary stents (Boston Scientific Corporation, MA,USA) are inserted to ensure adequate decompression and bile drainage.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: stent
Description: Patients with unresectable CCA are performed with ERCP, one or several plastic biliary stents (Boston Scientific Corporation, MA,USA) are inserted to ensure adequate decompression and bile drainage.
Study: NCT00398554

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: involved field irradiation, single daily fractions 1,5 Gy to max. 1,8 Gy standard dose 20 Gy, max dose 30 Gy (boost irradiation if required)
Study: NCT01719354

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community Health center
Description: Observation of the functioning and coordination of health care before discharge to own home.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: standard aftercare in hospital/mental health centers of District Psychiatric Service (DPS).
Study: NCT01054170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD9668
Description: 2 x 30 mg oral tablets twice daily (bid) for 12 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 x matched placebo to oral tablet twice daily (bid) for 12 weeks
Study: NCT00757341

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKI-606
Study: NCT03500601

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nut components
Description: nut components consumed daily for a period of 28 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo consumed daily for a period of 28 days
Study: NCT03945682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapist
Description: Intervention therapist at 2 centres providing 8 week intervention programme 50% embedded qualitative study
Study: NCT02851485

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972 600 mg oral solution fasted
Description: dosing after overnight fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972 600 mg oral tablet fasted
Description: dosing after overnight fasting

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG1972 600 mg oral tablet fed
Description: dosing after high-fat high-calorie breakfast
Study: NCT02216045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon, Ribavirin, camel milk
Description: Peginterferon One subcutaneous injection containing 0.5 ml solution with180 mcg PegIFNα-2a per week for 12 weeks.~Ribavirin (RBV) tablets (body-weight adjusted dose: \< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) taken orally (by mouth) once daily for for 12 weeks .~camel milk 250 ml of raw camel milk will be consumed in 10 minutes orally twice daily for 12 weeks.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peginterferon, Ribavirin
Description: Peginterferon (PegIFNα-2a) One subcutaneous injection containing 0.5 ml solution with180 mcg PegIFNα-2a per week for 12 weeks.~Ribavirin (RBV) tablets (body-weight adjusted dose: \< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) taken orally (by mouth) once daily for for 12 weeks.
Study: NCT04040504

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ERCP procedure with Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC)
Description: ERCP procedure using Pentax ED-34i10T2 Duodenoscope with Disposable Cap (DEC) and any necessary accessories.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ERCP procedure with Pentax ED-34i10T Duodenoscope
Description: ERCP procedure using Pentax ED-34i10T Duodenoscope with any necessary accessories.
Study: NCT01258413

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic Radical Hysterectomy + pelvic lymphadenectomy
Description: uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament + pelvic lymphadenectomy are removed by laparoscopic approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal radical hysterectomy
Description: uterus, upper 1-2cm of vagina , parametrial tissue and uterosacral ligament + pelvic lymphadenectomy are removed by abdominal approach
Study: NCT00329511

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methyldopa vs. clonidine
Description: Comparison of compliance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methyldopa vs. clonidine
Description: Comparison of compliance

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clonidine patch
Description: methyldopa 250 - 750 mg qid clonidine patch 0.1 - 0.4 mg q week

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: clonidine patch
Description: methyldopa 250 - 750 mg qid clonidine patch 0.1 - 0.4 mg q week
Study: NCT02561065

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: 1. Each participant will receive 12 personalized lifestyle counseling sessions given face-to-face by a trained practitioner.~2. The Fitbit physical activity tracker gives summaries of the participant's physical activity, provides stimulating prompts and rewards, and allows for social media sharing and competition.~3. A Sit-stand workstation allows to adjust the height of the participant workstation, including the computer screen, keyboard and mouse and allows them to easily switch between sitting and standing throughout the workday.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Description: 1. Each participant will receive 12 personalized lifestyle counseling sessions given face-to-face by a trained practitioner.~2. The Fitbit physical activity tracker gives summaries of the participant's physical activity, provides stimulating prompts and rewards, and allows for social media sharing and competition.~3. A Sit-stand workstation allows to adjust the height of the participant workstation, including the computer screen, keyboard and mouse and allows them to easily switch between sitting and standing throughout the workday.
Study: NCT01129466

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplement A followed by Supplement B
Description: Supplement A (3 days of Broccosprout homogenate) will be followed at least 2 weeks later by Supplement B (3 days of Broccosprout sandwich and SFN rich tea)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Supplement B followed by Supplement A
Description: Supplement B (Broccosprout sandwich and SFN rich tea for 3 days) followed at least 2 weeks later by 3 days of Supplement A (Broccosprout homogenate)
Study: NCT02269332

Intervention type: OTHER
Intervention: Screening Colonoscopy
Description: we will obtain serum vitamin D blood levels from those scheduled for a screening colonoscopy or polyp surveillance
Study: NCT04565379

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NuSepin® 0.1 mg
Description: NuSepin® 0.1 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NuSepin® 0.2 mg
Description: NuSepin® 0.2 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal Saline
Study: NCT00226837

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Nitrous oxide
Description: nitrous oxide by inhalation during induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide
Description: nitrous oxide by inhalation during induction

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitrous oxide
Description: nitrous oxide by inhalation during induction
Study: NCT03451617

Intervention type: DEVICE
Group type: OTHER
Intervention: Stent delivery with Xpedition
Description: Use of Xpedition stent delivery system to implant the XIENCE stent

Intervention type: DEVICE
Group type: OTHER
Intervention: Stent delivery with Alpine
Description: Use of Alpine stent delivery system to implant the XIENCE stent
Study: NCT03735212

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Services
Description: Participants receive enhanced services over a period of 6 months to support substance abuse recovery, referral to treatment, and parenting skills.
Study: NCT03824639

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured exercise
Description: Exercise instruction and encouragement

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health Education
Description: Provision of general information about a variety of health topics
Study: NCT01457989

Intervention type: DRUG
Intervention: retigabine/ezogabine
Description: dose range up to 1200 mg/day
Study: NCT04322838

Intervention type: DIAGNOSTIC_TEST
Intervention: MeDALL questionnaire for allergic diseases
Description: Questionnaire about allergic symptoms and disease

Intervention type: DIAGNOSTIC_TEST
Intervention: MeDALL questionnaire for allergic diseases
Description: Questionnaire about allergic symptoms and disease

Intervention type: DIAGNOSTIC_TEST
Intervention: Registration of allergic symptoms
Description: Daily registration of allergic symptoms from eyes, nose and lungs on scale from 0-10 and daily registration of use of anti allergic medication from 1st of August to 15th of October.

Intervention type: DIAGNOSTIC_TEST
Intervention: Registration of allergic symptoms
Description: Daily registration of allergic symptoms from eyes, nose and lungs on scale from 0-10 and daily registration of use of anti allergic medication from 1st of August to 15th of October.

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin Prick Test
Description: Diagnostic skin test for sensitization to allergens

Intervention type: DIAGNOSTIC_TEST
Intervention: Skin Prick Test
Description: Diagnostic skin test for sensitization to allergens

Intervention type: DIAGNOSTIC_TEST
Intervention: Specific IgE in serum
Description: Diagnostic test for sensitization to allergens in serum

Intervention type: DIAGNOSTIC_TEST
Intervention: Specific IgE in serum
Description: Diagnostic test for sensitization to allergens in serum

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasal provocation test
Description: Diagnostic test for allergic rhinitis. Patients and controls are exposed to an allergen with a nasal spray. Allergic reactions are measured with Linder score and Pean Nasal Inspiratory Flow (PNIF)

Intervention type: DIAGNOSTIC_TEST
Intervention: Nasal provocation test
Description: Diagnostic test for allergic rhinitis. Patients and controls are exposed to an allergen with a nasal spray. Allergic reactions are measured with Linder score and Pean Nasal Inspiratory Flow (PNIF)

Intervention type: DIAGNOSTIC_TEST
Intervention: Basophil Activation Test
Description: Basophil leukocytes are extracted from full blood and exposed to 6 different doses of allergen and activation of basophils are measured.

Intervention type: DIAGNOSTIC_TEST
Intervention: Basophil Activation Test
Description: Basophil leukocytes are extracted from full blood and exposed to 6 different doses of allergen and activation of basophils are measured.
Study: NCT02364791

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: standard techniques used to achieve air leak control

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: standard techniques used to achieve air leak control

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemopatch
Study: NCT01195051

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic medication reconciliation
Description: A new, computer-based application will be used to document and prescribe outpatient medications in the inpatient setting.
Study: NCT02041234

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Roux-en-Y Gastric Bypass (RYGB)
Description: Roux-en-Y Gastric Bypass (RYGB) as per standard surgical protocol, with a 30 cc gastric pouch, 50 cm biliopancreatic limb and 100cm gastrointestinal limb.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Incretin analogues
Description: Incretin analogues: Liraglutide up to 1.8 mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Xenical
Description: Xenical: Up to 120 mg tds

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SGLT2 inhibitors
Description: SGLT2 inhibitors: Empagliflozin up to 25mg daily, Canagliflozin up to 300mg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DPP-4 Inhibitors
Description: Sitagliptin up to 100 mg daily, Linagliptin up to 5mg daily
Study: NCT02359682

Intervention type: OTHER
Intervention: No intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No intervention
Description: No Intervention
Study: NCT03186131

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibandronate
Description: To examine the efficacy of oral Ibandronate in osteoporosis

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Ibandronate and Vitamin D
Description: To examine the efficacy of oral Ibandronate and Vitamin D in osteoporosis
Study: NCT02628782

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: InSeal's Vascular Closure Device
Description: Intravascular closure device
Study: NCT03594604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone
Description: Women desiring to postpone their periods may be randomized to norethindrone 5mg three times daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral contraceptive pill
Description: Women desiring to postpone their periods may be randomized to daily oral contraceptive pills.
Study: NCT04557943

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolotherapy
Description: Prolotherapy injection is performed intra-articularly and extra-articularly by a physician. Intra-articular injection with 25% dextrose will be carried out with the following details: 5 mL of 40% dextrose, 2 mL of lidocaine, and 1 mL of aqua dest are inserted into the 10-mL syringe, then 5 mL are injected with the superolateral approach. An extra-articular injection with 15% dextrose will be carried out with the following details:~in the 10-mL syringe 4 mL of 40% dextrose, 2 mL lidocaine, and 4 mL of distilled water are injected, to make a total of 30-40 mL injections. Treatment will be carried out on day 1st, 29th, and 57th.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium Hyaluronate
Description: Hyaluronan sodium injection is performed intra-articularly using 2 mL of Adant® Disposable. The treatment will be given five times, on day 1st, 8th, 15th, 22nd, and 29th
Study: NCT02649946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Covera Vascular Covered Stent following PTA
Description: Treatment of stenoses with primary percutaneous transluminal angioplasty (PTA) and placement of the Covera Vascular Covered Stent.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Transluminal Angioplasty (PTA) with Uncoated PTA Balloon
Description: Treatment of stenoses with PTA only
Study: NCT03687047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: New complete dentures
Description: Preliminary impressions using stock trays and impression compound; primary casts fabricated to make custom trays for definitive impressions; definitive impressions using zinc oxide eugenol impression paste; definitive impressions poured with type III dental stone to obtain mastercasts; jaw relations will be recorded, and the casts will be mounted on the articulator; the artificial acrylic resin teeth will be arranged, esthetics will be verified, and the trial dentures will be flasked and polymerized (72°C per 12 hours). The dentures will be finished and polished for insertion and follow-up.
Study: NCT03655821

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Dosing is either based on BSA or renal function

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Dosing is either based on BSA or renal function
Study: NCT03012607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Participants will be randomized into 1 of 3 groups (10 participants/group) to receive a controlled number of doses of tenofovir disoproxil fumarate (TDF, 300mg) in a combination pill with emtricitabine (FTC, 200mg) (Truvada®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Participants will be randomized into 1 of 3 groups (10 participants/group) to receive a controlled number of doses of tenofovir disoproxil fumarate (TDF, 300mg) in a combination pill with emtricitabine (FTC, 200mg) (Truvada®)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Truvada
Description: Participants will be randomized into 1 of 3 groups (10 participants/group) to receive a controlled number of doses of tenofovir disoproxil fumarate (TDF, 300mg) in a combination pill with emtricitabine (FTC, 200mg) (Truvada®)
Study: NCT01047293

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: RAD001 (everolimus) is a novel oral derivative of rapamycin.~RAD001 is being investigated as an anticancer agent based on its potential to act:~* Directly on the tumor cells by inhibiting tumor cell growth and proliferation~* Indirectly by inhibiting angiogenesis leading to reduced tumor vascularity (via potent inhibition of tumor cell HIF-1 activity, VEGF production and VEGF-induced proliferation of endothelial cells). The role of angiogenesis in the maintenance of solid tumor growth is well established, and the mTOR pathway has been implicated in the regulation of tumor production of proangiogenic factors as well as modulation of VEGFR signaling in endothelial cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFOX
Description: FOLFOX regimens combine oxaliplatin and leucovorin with bolus and infusional 5-fluorouracil (5-FU). 1 Oxaliplatin is a DNA cross-linking agent consisting of a platinum ion chelated with1, 2-diaminocyclohexane (DACH) and an oxalate ligand. It undergoes spontaneous activation in aqueous solutions via displacement of the labile oxalate ligand by water. The activated compounds bind with DNA, resulting in inter- and intra-strand platinum-DNA crosslinks. 5-FU is an anti-metabolite that blocks the methylation reaction of deoxyuridylic acid to thymidylic acid, causing thymidine-less cell death in rapidly growing cells. Leucovorin is reduced folic acid that modulates the activity of 5-FU by stabilizing the ternary 5-FdUMP/ thymidylate synthetase complex. Side effects associated with FOLFOX include neuropathy including pharyngo-laryngodysesthesia, diarrhea, nausea, vomiting, and mild myelosuppression.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab, a monoclonal antibody directed against VEGF (vascular endothelial growth factor) has been studied in a multitude of Phase I, II, and III clinical trials in more than 5000 patients in multiple tumor types. Phase III data in metastatic cancers
Study: NCT01045395

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Corn starch
Description: 90mg/d

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Unique Marine Algae Concentrate (UMAC)
Description: 90mg/d

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Golden brown algae
Description: 90mg/d
Study: NCT01209780

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV
Description: Investigational egg-derived trivalent subunit influenza vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TIV
Description: Investigational egg-derived trivalent subunit influenza vaccine.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIVf
Description: US licensed trivalent inactivated subunit influenza vaccine -Fluvirin (Novartis Vaccines and Diagnostics) is approved for use in subjects ≥4 years.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: TIVf
Description: US licensed trivalent inactivated subunit influenza vaccine -Fluvirin (Novartis Vaccines and Diagnostics) is approved for use in subjects ≥4 years.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparator TIV
Description: US licensed trivalent subunit inactivated influenza vaccine- Fluzone (Sanofi Pasteur) is approved for use in children \<4 years.
Study: NCT04510831

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Refined maize with extrinsic addition of labelled FeSO4
Description: Porridge prepared with refined maize flour with extrinsic addition of FeSO4 (isotopic iron 54)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T.molitor native chitin
Description: Porridge prepared with dried intrinsically labelled T.molitor (isotopic iron 57) native chitin, refined maize flour and extrinsic addition FeSO4 (isotopic iron 58)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: T molitor reduced chitin
Description: Porridge prepared with dried intrinsically labelled T.molitor (isotopic iron 57) reduced chitin, refined maize flour and extrinsic addition FeSO4 (isotopic iron 58)
Study: NCT02325427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: tDCS could deliver either real or sham stimulation.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: tDCS
Description: tDCS could deliver either real or sham stimulation.
Study: NCT04280068

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinician Guide (CG)
Description: An evidence-based, intervention approach to reduce heavy drinking in primary care settings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinician Guide (CG)
Description: An evidence-based, intervention approach to reduce heavy drinking in primary care settings.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinician Guide plus HealthCall
Description: HealthCall is a smartphone application designed to help participants keep track of their daily alcohol use, medication adherence and a few other health behaviors through brief daily use.
Study: NCT00679627

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galantamine
Description: 8mg/ day oral capsule increased to 16mg/day then to 24 mg per day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo